Role of the ERK1/2 pathway in tumor chemoresistance and tumor therapy
Role of the ERK1/2 pathway in tumor chemoresistance and tumor therapy
复制标题
ERK1/2通路在肿瘤化疗耐药和肿瘤治疗中的作用
DOI：
10.1016/j.bmcl.2014.11.076
复制
发表时间：
2015-01-15
影响因子：
2.7
通讯作者：
Zheng, Jun-Nian
中科院分区：
文献类型：
--
作者：
Liu, Qing-Hua;Shi, Mei-Lin;Zheng, Jun-Nian
化疗是治疗肿瘤的重要手段之一。然而，许多肿瘤患者可能会因为化疗耐药性导致的治疗失败而经历肿瘤复发。尽管许多信号通路都能影响肿瘤细胞的化疗耐药性，但细胞外信号调节激酶1和2（extracellularsignal-regulatedkinase 1 and 2，ERK 1/2）通路因其信号转导的重要性和与其他信号通路的相互干扰而受到广泛关注。大量研究表明，ERK 1/2通路参与了多种恶性肿瘤的化疗耐药。本文就ERK 1/2信号通路在肿瘤耐药及治疗中的作用作一综述。全面了解ERK 1/2通路在肿瘤耐药中的作用，将为肿瘤的治疗策略提供新的思路。(C)2014爱思唯尔有限公司版权所有。
Chemotherapy is one of the important methods for treatment in tumors. However, many tumor patients may experience tumor recurrence because of treatment failure due to chemoresistance. Although many signaling pathways could influence chemoresistance of tumor cells, the extracellular signal- regulated kinase 1 and 2 (ERK1/2) pathway has gained significant attention because of its implications in signaling and which has crosstalk with other signaling pathways. Extensive studies conclude that ERK1/2 pathway is responding to chemoresistance in many kinds of malignant tumors. The aim of this review is to discuss on the role of ERK1/2 pathway in chemoresistance and therapy of tumors. A comprehensive understanding of ERK1/2 pathway in chemoresistance of tumors could provide novel avenues for treatment strategies of tumors. (C) 2014 Elsevier Ltd. All rights reserved.